hotspot -WSS

hotspot

author：focus 2025-09-27 12:48:47 - browse：82

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： The Harvard botanist who searched for psychedelics in the Amazon

focus

WSS

Dana Farber says 6 studies to be retracted and 31 corrected

FDA sets aggressive timeline for overhauling inspection procedures

Cardiologists urge adding sexual orientation, gender identity to health records

Obesity drugs seen as possible treatment for liver disease MASH

Dana Farber says 6 studies to be retracted and 31 corrected

Why palliative psychiatry is worth discussing

focus

hotspot

knowledge

Affirmative action in medical school literally saved lives

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

PBM reform efforts get punted in Congress

Walensky prepares to leave CDC — and Congress — behind

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Bright Health sells Medicare Advantage business to Molina

STAT readers on older presidents, polypills, Medicare, and more

Bright Health sells Medicare Advantage business to Molina

With competition flaring, obesity drug hits goal in liver disease study

Wikipedia

Inaction leaves children at risk from dangerous chemotherapy drug

Medicare drug price lawsuits could be good politics for Biden

Dario to buy mental health app maker Twill in cash and stock deal

Immunocompromised patients offer clues on chronic Covid

He's a Nobel laureate. Critics say he was misleading on Covid

Alabama frozen embryo ruling has major implications for IVF clinics

hotspot

focus

explore

hotspot